SimBioSys receives FDA clearance for AI breast cancer recurrence tool
SimBioSys's AI-based breast cancer recurrence tool has received FDA clearance. The news was reported on 15 October 2026.
Who is affected and how
- doctor
- Oncologists and breast surgeons should consider how recurrence-risk prediction could fit into treatment decisions.
- medtech company
- Another example that prognostic software can also reach FDA clearance, a benchmark for companies' own submissions.
- hospital manager
- Oncology services should assess whether the tool is needed and what implementing it would cost.
Sources
- SimBioSys Earns FDA Clearance for AI Breast Cancer Recurrence Toolmedical product outsourcing · Oct 15, 2026
- FDA Clears First MRI-Derived AI Software for Assessing Breast Cancer Recurrence Riskdiagnostic imaging · Oct 16, 2026
- AI tool receives FDA clearance to predict breast cancer recurrencewftv.com · Oct 16, 2026
- SimBioSys nabs FDA clearance for Nvidia-powered, MRI-derived breast cancer recurrence tool - Fierce Biotechfiercebiotech.com · Oct 16, 2026
- FDA clears the first AI that predicts breast cancer recurrence from an MRI: the hard part will be proving its value · Zendoriczendoric.com · Oct 17, 2026
- Matthew Kurian: FDA Clears AI Tool to Predict Breast Cancer Recurrence Risk Before Surgery - OncoDailyoncodaily.com · Oct 18, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.